SLC25A15

Across TCGA pan-cancer cohorts, SLC25A15 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC25A15 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC25A15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A15 expression acts as an unfavorable survival marker.

BLCA, STAD, and UCEC are the cancer types where SLC25A15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.059	0.720	<.001	24	view →
STAD	OS	Median	III,IV	0.001	0.633	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC25A15–BLCA (OS)

Open the BLCA breakdown →